RWA Wealth Partners LLC Grows Stock Holdings in Amgen Inc. $AMGN

RWA Wealth Partners LLC boosted its holdings in shares of Amgen Inc. (NASDAQ:AMGN) by 30.6% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 45,213 shares of the medical research company’s stock after purchasing an additional 10,588 shares during the period. RWA Wealth Partners LLC’s holdings in Amgen were worth $12,759,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Legacy Investment Solutions LLC acquired a new position in shares of Amgen in the 2nd quarter valued at about $27,000. Evelyn Partners Investment Management LLP purchased a new stake in Amgen in the 2nd quarter worth approximately $32,000. Howard Hughes Medical Institute acquired a new position in shares of Amgen in the 2nd quarter valued at $32,000. Quaker Wealth Management LLC increased its holdings in Amgen by 200.0% in the 2nd quarter. Quaker Wealth Management LLC now owns 120 shares of the medical research company’s stock worth $34,000 after acquiring an additional 240 shares in the last quarter. Finally, Cloud Capital Management LLC acquired a new position in shares of Amgen during the 3rd quarter worth about $34,000. 76.50% of the stock is owned by institutional investors and hedge funds.

Amgen Trading Up 0.9%

Shares of AMGN opened at $382.87 on Wednesday. The firm’s 50-day moving average is $345.41 and its two-hundred day moving average is $317.87. The firm has a market capitalization of $206.39 billion, a P/E ratio of 26.91, a PEG ratio of 3.76 and a beta of 0.46. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a twelve month low of $261.43 and a twelve month high of $385.12.

Amgen (NASDAQ:AMGN) last released its quarterly earnings data on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share for the quarter, beating the consensus estimate of $4.76 by $0.53. The firm had revenue of $9.87 billion during the quarter, compared to the consensus estimate of $9.46 billion. Amgen had a return on equity of 148.37% and a net margin of 20.98%.Amgen’s quarterly revenue was up 8.6% on a year-over-year basis. During the same period last year, the business posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts predict that Amgen Inc. will post 20.62 earnings per share for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date of this dividend is Friday, February 13th. This is a positive change from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio is currently 70.84%.

Amgen News Roundup

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Market commentary highlighting recent share-strength and valuation checks has drawn fresh investor attention, supporting momentum off strong YTD and 1‑year returns. Amgen (AMGN) Valuation Check After Recent Share Price Strength And Analyst Fair Value Debate
• Positive Sentiment: Multiple articles argue Amgen is a long-term value/dividend play, reinforcing buy-and-hold interest from income and value-focused investors. Why Amgen (AMGN) is a Top Value Stock for the Long-Term (Zacks)
• Positive Sentiment: Amgen scheduled a presentation at the TD Cowen Health Care Conference (March 2), giving management a platform to update on commercial outlook and the MARITIME trial timetable — a likely near‑term liquidity for investor sentiment. AMGEN TO PRESENT AT THE 46TH ANNUAL TD COWEN HEALTH CARE CONFERENCE
• Neutral Sentiment: Short interest data posted shows zero shares and a short-interest ratio of 0.0 days — this appears to be a reporting anomaly and doesn’t provide a clear signal on bearish positioning.
• Neutral Sentiment: Feature pieces and retrospectives on long‑term returns (Benzinga, MSN) boost narrative momentum but are not new fundamental catalysts. If You Invested $100 In Amgen Stock 15 Years Ago, You Would Have This Much Today
• Negative Sentiment: Barclays initiated coverage with an Equal Weight rating and a $185 price target — a relatively conservative view that could cap upside and prompt some profit‑taking or more cautious positioning among institutional holders. Barclays Begins Amgen (AMGN) Coverage, Notes Balanced Outlook Despite Trial Debate

Analysts Set New Price Targets

A number of analysts have recently issued reports on AMGN shares. Wells Fargo & Company lifted their price target on Amgen from $325.00 to $375.00 and gave the stock an “equal weight” rating in a research note on Thursday, February 19th. UBS Group raised their price target on shares of Amgen from $380.00 to $390.00 and gave the stock a “buy” rating in a report on Monday, January 26th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Amgen from $285.00 to $295.00 and gave the company a “hold” rating in a research report on Thursday, February 5th. HSBC reiterated a “buy” rating and set a $425.00 target price on shares of Amgen in a research report on Wednesday, December 10th. Finally, Royal Bank Of Canada boosted their target price on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a report on Wednesday, February 4th. One investment analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, eleven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, Amgen currently has an average rating of “Moderate Buy” and an average price target of $351.76.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.